Skip to main content
Clinical Trials/NCT04242251
NCT04242251
Completed
Not Applicable

Novel Palliative Care Model for Advanced Cancer Patients: A Randomized Controlled Trial Study

National Cancer Centre, Singapore1 site in 1 country239 target enrollmentFebruary 8, 2021
ConditionsCancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cancer
Sponsor
National Cancer Centre, Singapore
Enrollment
239
Locations
1
Primary Endpoint
Functional Assessment of Cancer Therapy- General
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This is a randomized controlled trial of the 'Supportive and Palliative care Review Kit in Locations Everywhere' (SPARKLE) intervention, an outpatient-based model of early palliative care. The SPARKLE intervention comprises regular symptom monitoring using questionnaires, early identification and prompt treatment of problems identified. Proactive screening for problems facilitates earlier palliative care interventions for advanced cancer patients, whenever needs arise.

Detailed Description

This is a randomized controlled trial to compare clinical outcomes between advanced cancer patients receiving and not receiving care from the SPARKLE care model, in addition to current oncologic-led palliative care model. The hypothesis is that the SPARKLE care model results in a) improved quality of life of both advanced cancer patients and their caregivers, and b) reduced acute healthcare utilization and costs by these patients. Primary Study Aim: To determine the incremental effect of SPARKLE in addition to usual oncologist-led care on quality of life of advanced cancer patients. Patients' quality of life will be measured at baseline before randomization and 16 weeks after randomization using the Functional Assessment of Cancer Therapy - General (FACT-G). Secondary Study Aim 1: To determine the incremental effect of SPARKLE in addition to usual oncologist-led care on caregivers' quality of life. Caregiver quality of life will be measured at baseline before randomization and 16 weeks after randomization using the Singapore Caregiver Quality of Life Scale (SCQOLS), which was validated among caregivers of advanced cancer patients in Singapore.17 The PI was part of the team, led by the applicant's mentor, that developed the SCQOLS. Secondary Study Aim 2: To determine the effect of SPARKLE in addition to usual oncologist-led care on healthcare utilization and total healthcare costs, including the costs of delivering SPARKLE, from randomization until death. Healthcare utilization and cost data will be extracted from medical and billing data. SPARKLE costs will be captured prospectively using an Activity Based Costing Approach. The study hypothesis is that per capita healthcare costs will be lower in the SPARKLE model due to fewer admissions and shorter hospital lengths of stay when admitted. A prospective randomized controlled trial design will be used to test the effectiveness of the SPARKLE model. The recruitment target is 240 patients with advanced cancers, defined as stage 4 solid tumors including lung, colorectal, nasopharyngeal and pancreatic cancers. Eligible participants are randomized to usual care or SPARKLE intervention group using randomized permuted blocks method generated by an independent statistician, with block size kept unknown to the clinical investigators/site personnel. A total of 240 caregivers will be recruited. The study will take place in the National Cancer Centre of Singapore (NCCS).

Registry
clinicaltrials.gov
Start Date
February 8, 2021
End Date
January 31, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
National Cancer Centre, Singapore
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult aged 21 and above
  • Stage 4 solid tumor
  • Patient participants

Exclusion Criteria

  • Unable to complete patient-reported outcome measures
  • Already under the care of an existing palliative care service
  • Caregiver participants Inclusion Criteria:
  • Adult aged 21 and above
  • Caregiver participants Exclusion Criteria:
  • Unable to complete Singapore Caregiver Quality of Life Scale questionnaire
  • Employed caregiver to patient participants

Outcomes

Primary Outcomes

Functional Assessment of Cancer Therapy- General

Time Frame: 16 weeks

Quality of life is scored on a scale of 0 to 108, with higher scores indicating better outcomes

Secondary Outcomes

  • Singapore Caregiver Quality of Life Scale(16 weeks)

Study Sites (1)

Loading locations...

Similar Trials